Novartis
Novartis scores EU approval in acute myeloid leukaemia and advanced systemic mastocytosis
September 20, 2017Research and Development, Sales and Marketing EU, Europe, Novartis, acute myeloid leukaemia, advanced systemic mastocytosis, pharma, pharmaceutical
Novartis has announced that its targeted therapy Rydapt (midostaurin) has received EU approval in the two rare cancer indications: newly …
Novartis’ Xolair shows strong retreatment efficacy at Phase 3 in chronic spontaneous urticaria
September 18, 2017Research and Development, Sales and Marketing Novartis, Xolair, chronic spontaneous urticarial, pharma, pharmaceutical
Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a …
Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data
September 15, 2017Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical
Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …
Novartis’ Cosentyx proves long-term efficacy in psoriasis skin clearance
September 13, 2017Research and Development Cosentyx, Novartis, pharma, pharmaceutical, psoriasis
At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx …
FDA accepts license application for Novartis’ rituximab biosimilar
September 12, 2017Manufacturing and Production, Sales and Marketing Novartis, Rituxan, Sandoz, biosimilar, rituximab
Sandoz, Novartis’ generics and biosimilars division, has revealed that the FDA has accepted its Biologics License Application (BLA) for a …
Melanoma treatment: Novartis posts success, Roche stumbles
September 11, 2017Research and Development, Sales and Marketing Novartis, Roche, biotech, drugs, melanoma, pharma, pharmaceutical
In a perfect example of the competitive nature of the pharmaceutical industry, just as one company posted success in one …
Novartis exec designated as new CEO after Jimenez announces retirement
September 5, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, a, joe jimenez, phar, pharma, pharmaceuticals
Novartis has announced that its Chief Executive, Joe Jimenez, is set to retire next year. In his place, Vasant Narasimhan …
Novartis celebrates success of Gilenya in paediatric multiple sclerosis
September 5, 2017Manufacturing and Production, Research and Development MS, Novartis, gilenya, health, multiple sclerosis, pharma, pharmaceuticals
Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …
Novartis CEO Jimenez announces retirement in 2018
September 4, 2017Sales and Marketing Novartis, Vasant Narasimhan, joe jimenez, pharma, pharmaceuticals
Novartis has announced that its Chief Executive, Joe Jimenez (pictured), is set to retire next year. In his place, Vasant …
CAR-T treatment is given ‘historic’ first approval by FDA
August 31, 2017Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical
Novartis has received approval for its CAR-T treatment of paediatric and young adults with a form of acute lymphoblastic leukaemia …
Novartis names new Chief Digital Officer
August 29, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, appointment
Novartis has announced that it has appointed a new Chief Digital Officer in the form of Bertrand Bodson, who will …
Novartis’ drug prevents heart attacks and cancer but faces major challenges
August 29, 2017Manufacturing and Production, Research and Development Novartis, biotech, drugs, pharma, pharmaceutical
It would be expected that when a company releases data to show that its drug, previously only used in a …
Novartis names new Chief Digital Officer
August 24, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, appointment, digital pharma, life sciences, pharma, pharmaceuticals
Novartis has announced that it has appointed a new Chief Digital Officer in the form of Bertrand Bodson, who will …
Novartis gets EU nod for potential blockbuster breast cancer drug
August 24, 2017Sales and Marketing CDK4/6, Novartis, biotech, breast cancer, drugs, pharma, pharmaceutical
Novartis has released that it has received marketing approval from the European Commission for its drug for the treatment of …
Novartis launches first large-scale smartphone-based study in multiple sclerosis
August 23, 2017Research and Development MS, Novartis, life sciences, multiple sclerosis, pharma, pharmaceuticals
Novartis has launched what it claims is the first large-scale mobile research study which will gather data on multiple sclerosis …
Latest content
FibroFind appoints Lee Borthwick as CEO
